Aethlon Medical to merge with North Immunology to advance NOR-101
North Immunology’s lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody for atopic dermatitis, targeting both type 2 and non-type 2 inflammation.
North Immunology's lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 and non-type 2 inflammation, with the potential to deliver a best-in-disease treatment for patients with atopic dermatitis. The company said the private placement was oversubscribed and raised $180 million.